Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

This is a report arising from an ECNP expert meeting. Recent studies have focussed on cognitive problems in manic-depressive illness and a few have addressed premorbid neuropsychological functioning. The results are not fully consistent but seem to point to a neurodegenerative model, rather than a neurodevelopmental one, for some cognitive domains. There is agreement that cognitive dysfunction is highly correlated with psychosocial functioning. The neurobiological and clinical implications of recent findings will be discussed. Treatments to reduce subsyndromal symptoms and relapses may indirectly improve neurocognitive deficits and this should be better documented. Moreover, neurocognitive impairment in bipolar disorder should be considered a potential therapeutic target, so that research should focus on new drugs and psychological interventions, including neurocognitive rehabilitation, addressed to improve not only the cognition but also the functional outcome of this population.

Original publication

DOI

10.1016/j.euroneuro.2008.07.005

Type

Journal article

Journal

Eur Neuropsychopharmacol

Publication Date

11/2008

Volume

18

Pages

787 - 793

Keywords

Antimanic Agents, Bipolar Disorder, Cognition Disorders, Cross-Sectional Studies, Drug Therapy, Combination, Humans, Longitudinal Studies, Magnetic Resonance Imaging, Nervous System, Neurodegenerative Diseases